AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04583618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI
Description: Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Study NCT01952353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection plus Thrombectomy
Description: Liver resection plus Thrombectomy
Study NCT01952353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection plus Thrombectomy
Description: Liver resection plus Thrombectomy
Study NCT04583618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII
Description: Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Study NCT04583618 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13 - valent conjugate vaccine-Prevnar 13
Description: Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Study NCT04583618 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal Vaccine Polyvalent-Pneumovax 23
Description: Pharmaceutical form:Solution for injection Route of administration: intramuscular
Study NCT02371213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: social networking on mobile phone
Description: Audio-video media about serious complications such as labor pain, vaginal bleeding, water breaking and fewer fetal movement via social networking application on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly
Study NCT00628576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Description: UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
Study NCT00628576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin (Leo)
Description: FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
Study NCT02732977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: expert system development
Description: data collection (imaging, biology physiology ... ) of patients with systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization before and after implementation of the recommended standard treatments and modeling using mathematical and statistical models fed all data .
Study NCT02121301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose 0.155µg/mL SkQ1 ophthalmic solution
Description: eyedrops
Study NCT02121301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose 1.55µg/mL SkQ1 ophthalmic solution
Description: eyedrops
Study NCT02121301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle) opthalmic solution
Description: eyedrops
Study NCT01410123 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Integrated Stepped Care (ISC)
Description: 1. At risk drinking:~   Step 1: Brief negotiated interview (BNI) + booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction Physician Management + Alcohol pharmacotherapy~2. Alcohol abuse/dependence:~   Step 1: Addiction Physician Management + Alcohol Pharmacotherapy; Step 2: Motivational Enhancement Therapy; Step 3: Detoxification and aftercare~3. Moderate Alcohol + Liver Disease:~Step 1: Brief Negotiated Interview (BNI)+ booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction physician management + alcohol pharmacotherapy.
Study NCT01410123 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: The TAU arm will receive a handout with alcohol information embedded within general health-related information (exercise, smoking cessation, and flu vaccination) and standard care as provided by their treating physician. All patients will have access to a NIAAA informational website.
Study NCT01322802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine
Description: Given ID
Study NCT01322802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT05323760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET)
Description: A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute).
Study NCT00370331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
Study NCT00370331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
Study NCT01802567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Therapy- Pediatric Gene Analysis Platform
Description: A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
Study NCT04129697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone or Methylprednisolone
Description: steroids
Study NCT03623854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03623854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given via infusion
Study NCT04401852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSo4
Description: a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.
Study NCT04401852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: equal volume of isotonic 0.9% saline over 15-20 minutes
Study NCT02516020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Global
Description: Embryos are cultured in single step culture from day 1 to day 5
Study NCT02516020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Origio
Description: Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
Study NCT00553072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: 250 mg/kg/dose in 1 ml normal saline
Study NCT00553072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1 ml/kg/dose
Study NCT02030301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-HB01
Description: Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®
Study NCT02030301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-HM01
Description: Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®
Study NCT02030301 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PBS
Description: Phosphate-buffered saline
Study NCT01885520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting condition
Description: eperisone SR tablet 75mg administrated under fasting
Study NCT01885520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fed condition
Description: eperisone SR tablet 75mg administrated fed condition
Study NCT03461536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-first Clinical Decision Support tool
Description: Intervention: The intervention is the CDS tool, which consists of 4 components:~1. Four questions which assess the appropriateness of ultrasound for this patient~2. A link to the evidence~3. Buttons to remove CT scan and order ultrasound~4. If the CT scan order is kept, reasons why ultrasonography is not appropriate The CDS tool will be placed or integrated into EPIC, at the point of order entry. The tool will be triggered by an order for CT scan for kidney stone.~Appropriateness criteria for ultrasound:~1. Adults aged >18 and \< 76~2. Non-obese (men \< 285lbs, women \< 250lbs)~3. Low risk of Stone Emergency (Obstructing stone and any of the following: urosepsis, renal deterioration, post kidney transplant, solitary kidney, intractable symptoms)~4. Low risk of clinically significant alternative diagnosis (e.g. appendicitis, cholecystitis, AAA, ovarian torsion) If all responses are affirmative, then the subject should receive US, and US order is provided.
Study NCT02857569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab IT
Study NCT02857569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab IV
Study NCT02857569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab IV
Study NCT02857569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab IV
Study NCT00990977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness based stress reduction (MBSR)
Description: MBSR is an 8-week course covering a total of 24 contact hours where the group of patients meet with an clinical psychologist certified as mindfulness instructor. The group will train the ability of mindfulness by specific awareness improving practises (body-scan) guided meditations and soft yoga. Between group-sessions participants are recommended to practice 45 minutes daily and to go through instructions in MBSR hand-outs. Participants will be given audio-CDs containing instructions and guides to support home practice.
Study NCT01830959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast
Study NCT01830959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one a day
Study NCT01762501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 20mg/day
Study NCT01762501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg/day
Study NCT04359810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma (anti-SARS-CoV-2 plasma)
Description: Convalescent Plasma that contains antibody titers against SARS-CoV-2
Study NCT04359810 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-convalescent Plasma (control plasma)
Description: Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)
Study NCT04414111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Highly suppressive Treg measurement
Description: Circulating highly suppressive Treg measurement
Study NCT03396341 — intervention group
Intervention type: OTHER
Intervention: Salvia sample
Description: salvia sample
Study NCT03396341 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
Study NCT02783690 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: 40 Gy (RBE) in 15 daily fractions
Study NCT02800668 — intervention group
Intervention type: DEVICE
Intervention: DJBL (Duodenal jejunal bypass liner, EndoBarrier)
Description: Implantation of EndoBarrier after medical and patient's decision, Duration of treatment 12 months in maximum, follow up for 4 weeks after Explantation, follow up during treatment by physical examination, ECG control, sampling and analysis of blood parameters, mixed meal tolerance tests only for diagnostic purposes to assess gut hormonal changes and metabolic parameters
Study NCT01375140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 15 mg by mouth twice daily (BID), continuously in 28-day cycles.
Study NCT01375140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg by mouth each day on days 1-21, followed by 7 days of no therapy of each 28 day cycle.
Study NCT01375140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be added for patients who have not responded after 3 cycles of therapy.~30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued.
Study NCT02784080 — intervention group
Intervention type: OTHER
Intervention: HLA-alloantibodies exposure
Description: Following analyzes will be done:~LABScreen® Single Antigen, One Lambda, CA~C1qScren™, One Lambda, CA (planned for later study)~PE-conjugated IgG3 antibody (planned for later study)~LABScreen® Mixed, One Lambda, CA (never analysed in the study)
Study NCT03702127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: NIBS is applied to the brain.
Study NCT04073875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-GP1
Description: 18F-GP1 PET-CT scan
Study NCT04347798 — intervention group
Intervention type: OTHER
Intervention: Hydroxychloroquine/Chloroquine
Description: Prospective evaluation of development of Covid-19 in inflammatory arthritis patients on biologics with anti-malarials compared to inflammatory arthritis patients on biologics without anti-malarial exposure
Study NCT04339764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iPSC-derived RPE/PLGA transplantation
Description: iPSC-derived RPE/PLGA transplantation
Study NCT02725801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allergen one-port tissue expander placement
Description: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
Study NCT02725801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlloX2 two-port tissue expander placement
Description: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
Study NCT01912560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2003
Study NCT01912560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01912560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
Study NCT02861547 — intervention group
Intervention type: OTHER
Intervention: death
Study NCT00731809 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: FDG PET CT
Description: FDG PET CT
Study NCT00901706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Geriatric Assessment and APS Usual Care
Description: Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
Study NCT00901706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment and APS Usual Care
Description: Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
Study NCT00901706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APS usual care
Description: APS usual care consists of social, medical, and legal assistance.
Study NCT00901706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APS usual care
Description: APS usual care consists of social, medical, and legal assistance.
Study NCT02109315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamine C
Description: C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
Study NCT02109315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 6 mg
Description: Liraglutide endovenous de 0.6 mg. one time a day
Study NCT00497185 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-Based Cognitive Therapy for Functional Disorders
Description: Mindfulness-based cognitive therapy: A manualized program will be delivered by two instructors who are experienced cognitive therapists in eight weekly 3½-hour group training sessions and one follow-up session after a month involving up to 12 patients with somatoform disorders. The patients must be willing and able to attend and devote up to 1 hour per day for homework.~The therapy is compared with a group of controls receiving shared care defined as: Treatment as usual augmented by psychiatric consultation intervention: The patients are offered a psychiatric consultation after the assessment interview. It is the aim to optimise treatment in the present health care system.
Study NCT01218893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine prophylaxis
Description: The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01218893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis
Description: The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
Study NCT01218893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine prophylaxis
Description: The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
Study NCT01218893 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Immunization
Description: All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
Study NCT01218893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization
Description: All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
Study NCT01218893 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunization
Description: All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
Study NCT01218893 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasmodium falciparum challenge
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
Study NCT01218893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum challenge
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT02420717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV or PO
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV and PO
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02420717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT02420717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT04060303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative surgical care
Description: The ENRICH-US Protocol includes perioperative counseling and education, maintaining euvolumia through limited perioperative fasting and limited intraoperative fluid resuscitation, early enteral intake and mobilization, limited use of opioids, and non-routine use of surgical drains and tubes. Elements span the pre-, intra-, and post-operative experience for patients and involve care coordination among surgery, anesthesia, and nursing providers. Though individually simple, the concomitant implementation of the combined elements results in a markedly improved patient care experience that mitigates the physiologic stress of surgery and hastens recovery.